BriaCell Therapeutics (BriaCell Therapeutics) Float Percentage Of Total Shares Outstanding : 76.64% (As of May. 22, 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BriaCell Therapeutics's float shares is 14.01 Mil. BriaCell Therapeutics's total shares outstanding is 18.28 Mil. BriaCell Therapeutics's float percentage of total shares outstanding is 76.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BriaCell Therapeutics's Insider Ownership is 2.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BriaCell Therapeutics's Institutional Ownership is 1.73%.

BriaCell Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BriaCell Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	14.01	/	18.28
	=	76.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3